Long Ideas - Achillion Pharmaceuticals (NASDAQ:ACHN) is up nearly 80% since its summer lows (see our initial article on ACHN here), as the hepatitis C (HCV) space continues … Continue Reading
Read NowMost Popular - A bearish article from theStreet.com is pressuring shares of Hemispherx Biopharma (NASDAQ:HEB) Thursday morning, which comes shortly after the company announced a December 20th FDA … Continue Reading
Read NowMost Popular - Peregrine Pharmaceuticals (NASDAQ:PPHM) announced more bad news Thursday, after receiving a default notice from lender, Oxford Finance, on Monday. The default on the loan was … Continue Reading
Read NowLong Ideas - On Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that while it would be advancing its developmental Hepatitis C (HCV) treatment, ALS-2200, into Phase II testing, ALS-2158 didn’t … Continue Reading
Read NowLong Ideas - Wednesday morning, Catalyst Pharmaceutical Partners (NASDAQ:CPRX) announced that its previous guidance for top-line trial data at the end of September would be delayed until November. … Continue Reading
Read NowLong Ideas - Shares of ARIAD Pharmaceuticals (NASDAQ:ARIA) have been moving sporadically in the last week as traders test the limits of its latest range; ARIA set a … Continue Reading
Read NowLong Ideas - Shares of Pain Therapeutics (NASDAQ:PTIE) continue to rise as partner Pfizer (NYSE:PFE) continues to send signals that Remoxy’s New Drug Application (NDA) could be resubmitted … Continue Reading
Read Now